Search Results

MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formats Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings

In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced therapies.

Combining human iPSC biology and AI computing to accelerate drug discovery, improve drug safety, and advance precision medicine.

The agreement establishes a framework for cooperation between the African Medicines Agency (AMA) and the U.S. Pharmacopeia to strengthen regulatory systems, enhance capacity building, and improve access to quality-assured medical products across Africa.